SK海力士宣佈完成收購英特爾(INTC.US)NAND事業第一階段
南韓晶片製造商SK海力士表示,在中國國家市場監督管理總局於本月22日批準合併後,SK海力士今日完成了第一階段的後續流程,包括從英特爾(INTC.US)接管SSD業務及其中國大連NAND閃存製造工廠,SK海力士將支付70億美元作爲對價。
收購交易的第二階段預料將在2025年3月或之後完成,屆時SK海力士將支付剩餘20億美元,SK海力士的收購將納入英特爾NAND業務餘下資產以完成整項交易,包括NAND閃存晶圓的生產和設計知識產權,和人力資源。
總部位於美國加州聖荷西的SK海力士子公司Solidigm將管理新收購的SSD業務。SK海力士、Solidigm和英特爾將密切合作,直至交易完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.